N'-benzo[b]thien-2-ylmethyl-N'-[7-chloro-4-oxo-2-(pyrrolidine-1-carbonyl)-1,4-dihydroquinoline-3-carbonyl]hydrazinecarboxylic acid tert-butyl ester | 348628-27-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: N'-benzo[b]thien-2-ylmethyl-N'-[7-chloro-4-oxo-2-(pyrrolidine-1-carbonyl)-1,4-dihydroquinoline-3-carbonyl]hydrazinecarboxylic acid tert-butyl ester
• 英文别名: n'-Benzo[b]thien-2-ylmethyl-n'-[7-chlor-4-oxo-2-(pyrrolidine-1-carbonyl)-1,4-dihydroquinoline-3-carbonyl]hydrazinecarboxylic acid tert-butyl ester；tert-butyl N-[1-benzothiophen-2-ylmethyl-[7-chloro-4-oxo-2-(pyrrolidine-1-carbonyl)-1H-quinoline-3-carbonyl]amino]carbamate
• CAS: 348628-27-3
• 化学式: C₂₉H₂₉ClN₄O₅S
• 分子量: 581.092
• InChiKey: HGPAIIKEIDEAEX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.5
• 重原子数：
  40
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  136
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  N'-benzo[b]thien-2-ylmethyl-N'-[7-chloro-4-oxo-2-(pyrrolidine-1-carbonyl)-1,4-dihydroquinoline-3-carbonyl]hydrazinecarboxylic acid tert-butyl ester 在 甲烷磺酸 作用下， 以 四氢呋喃 为溶剂， 以88%的产率得到7-chloro-4-hydroxy-2-(benzo[b]thien-2-ylmethyl)-1,2,5,10-tetrahydropyridazino[4,5-b]quinoline-1,10-dione
  参考文献：
  名称：

  Pyridazinoquinolinetriones as NMDA Glycine-Site Antagonists with Oral Antinociceptive Activity in a Model of Neuropathic Pain

  摘要：

  A series of 7-chloro-2,3-dihydro-2-[1-(pyridinyl)alkyl]-pyridazino[4,5-b]quinoline-1,4,10(5H)-triones were synthesized and found to have potent activity at the glycine site of the NMDA receptor. In some cases, these compounds possessed poor aqueous solubility that may have contributed to poor rat oral bioavailability. Subsequently, compounds have been identified with improved aqueous solubility and oral bioavailability. Several of these compounds were examined in a rat chronic constrictive injury (CCI) model of neuropathic pain and found to have potent activity when dosed orally.

  DOI：

  10.1021/jm060212s
• 作为产物：
  描述：

  7-氯-4-羟基喹啉-2,3-二羧酸二甲酯 在 氢氧化钾 、 sodium hydroxide 、 N,N'-二环己基碳二亚胺 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 19.08h， 生成 N'-benzo[b]thien-2-ylmethyl-N'-[7-chloro-4-oxo-2-(pyrrolidine-1-carbonyl)-1,4-dihydroquinoline-3-carbonyl]hydrazinecarboxylic acid tert-butyl ester
  参考文献：
  名称：

  Pyridazinoquinolinetriones as NMDA Glycine-Site Antagonists with Oral Antinociceptive Activity in a Model of Neuropathic Pain

  摘要：

  A series of 7-chloro-2,3-dihydro-2-[1-(pyridinyl)alkyl]-pyridazino[4,5-b]quinoline-1,4,10(5H)-triones were synthesized and found to have potent activity at the glycine site of the NMDA receptor. In some cases, these compounds possessed poor aqueous solubility that may have contributed to poor rat oral bioavailability. Subsequently, compounds have been identified with improved aqueous solubility and oral bioavailability. Several of these compounds were examined in a rat chronic constrictive injury (CCI) model of neuropathic pain and found to have potent activity when dosed orally.

  DOI：

  10.1021/jm060212s

文献信息

• Method and composition for the treatment of pain
  申请人：——

  公开号：US20030162783A1

  公开（公告）日：2003-08-28

  A method for the treatment of pain is disclosed comprising administration of a pain-ameliorating effective amount of any compound according to structural diagram I; 1 wherein: A, D and R 1 are as defined in the specification. Also disclosed are pharmaceutical compositions comprising a pain-ameliorating effective amount of a compound in accord with structural diagram I.

  本发明公开了一种治疗疼痛的方法，包括给予按照结构式I的任何化合物的缓解疼痛有效量；其中：A、D和R1如规范中所定义。还公开了包括按照结构式I的化合物的缓解疼痛有效量的制药组合物。
• METHOD AND COMPOSITION FOR THE TREATMENT OF PAIN
  申请人：AstraZeneca AB

  公开号：EP1248621A1

  公开（公告）日：2002-10-16
• [EN] METHOD AND COMPOSITION FOR THE TREATMENT OF PAIN<br/>[FR] METHODE ET COMPOSITION DE TRAITEMENT DE LA DOULEUR
  申请人：ASTRAZENECA AB

  公开号：WO2001047523A1

  公开（公告）日：2001-07-05

  A method for the treatment of pain is disclosed comprising administration of a pain-ameliorating effective amount of any compound according to structural diagram (I), wherein: A, D and R1 are as defined in the specification. Also disclosed are pharmaceutical compositions comprising a pain-ameliorating effective amount of a compound in accord with structural diagram (I).